Life Biosciences Launches First Human Trial for Cellular Rejuvenation to Reverse Sight Loss

The FDA's first clearance of a cellular rejuvenation therapy for human trials marks a pivotal shift toward reversing biological aging rather than merely slowing it down. This study targeting the optic nerve could validate epigenetic reprogramming as a viable treatment for diverse age-related diseases beyond vision loss.